Human Paratuberculosis Foundation is dedicated to providing the most up-to-date information in our field to assist patients around the world in making informed decisions about their treatment. We are grateful for the support of this community and look forward to taking this journey together.
Read all the latest news and research about Mycobacterium avium subsp. paratuberculosis (MAP) and the treatment of Crohn’s and other diseases using AMAT therapy. Enjoy!
2017 MAP Conference | Treating MAP in Crohn’s Disease
Prof. Thomas Borody is a gastroenterologist who is the founder and Medical Director of the Centre for Digestive Diseases in Sydney, Australia. He has established novel therapies in gastrointestinal areas such as Inflammatory Bowel Disease, Irritable Bowel Syndrome, Parasite infestation, Resistant Helicobacter pylori and C. difficile. In this presentation, he discusses how he treats MAP-driven Crohn’s disease, treatment for fistulae, the synergy of infliximab and antibiotics, and antibiotics in treatment-naive patients. Anti-MAP therapy for pyoderma gangrenosum is also briefly discussed. A group of patients have long-term, medication free remission due to Anti-MAP therapy.
2017 MAP Conference | The Rationale for Antibiotics in Crohn’s Disease
Dr. Shafran is a gastroenterologist who has been practicing in the Orlando area since 1979. He has used Anti-MAP therapy as part of his practice, and talks about his experience treating patients, including why current therapies have no role in treating Crohn’s disease in his opinion. Research from Crohn’s patients who have been treated with antibiotics is presented. Deep mucosal healing and sustained remission was found in 11 patients over an 18 year period.
2017 MAP Conference | Rationale for Triple Antibiotic Therapy for MAP
Dr. Kalfus is a Medical Director at RedHill Biopharma, which is currently conducting a Phase III FDA trial of a specific combination of antibiotics in Crohn’s disease patients. In his presentation, Dr. Kalfus gives the reason behind triple therapy for MAP and how the three antibiotics were selected. He also talks about how the currently available Crohn’s therapies have some anti-MAP activity. MAP diagnostics, the Selby study and the ongoing RedHill study are also discussed.
2017 MAP Conference | Unacknowledged Growth Inhibition of MAP by Immunomodulators
Dr. Greenstein is a researcher in the Laboratory of Molecular Surgical Research at the VA Medical Center in Bronx, NY. He presents his research explaining why he believes that the primary action of current Crohn’s disease therapies is really Anti-MAP, and hypothesizes that Crohn’s disease may be the tip of the MAP iceberg. The antimycobacterial effect of Vitamin D is also discussed.